Radiopharm Theranostics vs TherapeuticsMD
RADX and TXMD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RADX and TXMD compare
TherapeuticsMD grew revenue faster over the last twelve months (33.9% versus −23.8% for Radiopharm Theranostics).
TherapeuticsMD scores higher on the StockData Score (10 against 6 for Radiopharm Theranostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RADX | TXMD |
|---|---|---|
| Size and price | ||
| Market cap | – | $21.6M |
| Share price | $0.760 | $1.87 |
| Change, 1 year | −83.8% | 11.3% |
| Change, 5 years | – | −93.4% |
| Beta (5Y) | 1.05 | 0.66 |
| Employees | 2 | 1 |
| StockData Score | ||
| Total score | 6 | 10 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 3 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 187× |
| P/S | – | 5.8× |
| P/B | – | 0.8× |
| Growth | ||
| Revenue growth (TTM) | −23.8% | 33.9% (better) |
| Revenue growth, 5Y average | – | −45.8% |
| Net income growth (TTM) | – | −59.6% |
| EPS growth (TTM) | – | −50.0% |
| Profitability | ||
| Gross margin | 9.5% | – |
| Operating margin | −2052% | −95.3% (better) |
| Net margin | – | 3.3% |
| Return on equity | – | 0.44% |
| Return on invested capital | – | −15.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −505.2× | – |
| Current ratio | 1.16 | 3.32 (better) |
| Altman Z-score | – | −33.69 |
| Piotroski F-score | – | 6 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 1.4% | 31.7% |
| Held by insiders | 27.5% | 1.6% |
| Insider net buying, 12 months | – | $14.0K |
| Short interest, % of float | – | 0.27% |
Go deeper
- RADX stock overview
- RADX income statement
- RADX valuation and score
- TXMD stock overview
- TXMD income statement
- TXMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.